;
Skip to main content
Home > The Daily Extra > Financial News

Chronological Index of : Financial News

 Current Issue
  • FINANCIAL NEWS: Aerpio raises $18 million in A-2 round

    Aerpio Therapeutics Inc. (Cincinnati, Ohio) raised $18 million in a series A-2 round led by new investor OrbiMed. Existing investors Novartis Venture Funds; Satter Investment Management; Kearny Venture Partners; Venture…

    Published on 4/23/2014
  • FINANCIAL NEWS: Amgen slides on 1Q14 miss

    Amgen Inc. (NASDAQ:AMGN) fell $5.99 to $113.32 on Wednesday after reporting 1Q14 earnings late Tuesday that missed the Street. Adjusted diluted EPS was $1.87 on revenues of $4.5 billion. The Street was expecting EPS of…

    Published on 4/23/2014
  • FINANCIAL NEWS: Biogen Idec beats on revenues, misses on EPS

    Biogen Idec Inc. (NASDAQ:BIIB) reported 1Q14 non-GAAP diluted EPS of $2.47, up from $1.97 in 1Q13, but below the Street's $2.56 estimate. First quarter revenues were $2.1 billion, up 51% from $1.4 billion in 1Q13 and …

    Published on 4/23/2014
  • FINANCIAL NEWS: Kala raises $22.5 million series B

    Kala Pharmaceuticals Inc. (Waltham, Mass.) raised $22.5 million in a series B round led by new investor Ysios Capital. An undisclosed new strategic investor also participated along with existing investors Crown Venture …

    Published on 4/23/2014
  • FINANCIAL NEWS: Quotient amends IPO

    Transfusion diagnostics company Quotient Ltd. (Penicuik, U.K.) amended its IPO and now plans to sell 5 million units at $8 on NASDAQ, which would raise $40 million. Each unit comprises a share and a warrant to purchase …

    Published on 4/23/2014
  • FINANCIAL NEWS: Amgen misses Street

    Amgen Inc. (NASDAQ:AMGN) reported 1Q14 adjusted diluted EPS of $1.87, missing by $0.07 the Street's estimate of $1.94 and down from $1.96 in 1Q13. First quarter revenues increased 7% to $4.5 billion, but missed the …

    Published on 4/22/2014
  • FINANCIAL NEWS: Cancer diagnostics play Guardant raises $30 million

    Guardant Health Inc. (Redwood City, Calif.) raised $30 million in a series B round led by new investor Khosla Ventures. Existing investor Sequoia Capital and new investor Pejman Mar Ventures also participated. In …

    Published on 4/22/2014
  • FINANCIAL NEWS: Pharma deals pump biotech, pharma indices

    A slew of multi-billion pharma deals helped biotech and pharma indices post better gains than the broader markets on Tuesday. The BioCentury 100 index gained 4.1%, the NASDAQ Biotechnology index was up 3.2%, the NYSE …

    Published on 4/22/2014
  • FINANCIAL NEWS: Principia secures $50 million in B round

    Principia Biopharma Inc. (South San Francisco, Calif.) raised an undisclosed amount in the first tranche of a $50 million series B round led by new investor Sofinnova Ventures. Existing investors Morgenthaler Ventures; …

    Published on 4/22/2014
  • FINANCIAL NEWS: Retinal disorder play Avalanche raises $55 million

    Avalanche Biotechnologies Inc. (Menlo Park, Calif.) raised $55 million in a series B round from new investors Venrock; Deerfield; Adage Capital Management; Redmile Group; Rock Springs Capital; Sabby Capital; an …

    Published on 4/22/2014
  • FINANCIAL NEWS: Sarepta planning $100 million follow-on

    Sarepta Therapeutics Inc. (NASDAQ:SRPT) proposed late Tuesday to raise up to $100 million in a follow-on underwritten by BofA Merrill Lynch and Morgan Stanley. On Monday, Sarepta jumped $9.58 (39%) to $33.98 after the …

    Published on 4/22/2014
  • FINANCIAL NEWS: Sovaldi sales hit $2.3 billion in first full quarter

    Gilead Sciences Inc. (NASDAQ:GILD) reported 1Q14 earnings late Tuesday, including $2.3 billion in sales of Sovaldi sofosbuvir in the HCV drug's first full quarter on the market. According to Deutsche Bank's Robyn …

    Published on 4/22/2014
  • FINANCIAL NEWS: Agios amends follow-on

    Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said it now plans to sell 2 million shares in a follow-on underwritten by JPMorgan; Goldman Sachs; Cowen; and Leerink. If sold at Agios' close of $48.42 on April 9, before the …

    Published on 4/21/2014
  • FINANCIAL NEWS: Infectious disease play ContraFect files for IPO

    ContraFect Corp. (Yonkers, N.Y.) filed to raise up to $23 million in an IPO on NASDAQ underwritten by Maxim Group. ContraFect is developing a class of enzymes called lysins, which break open the cell walls of Gram-…

    Published on 4/21/2014
  • FINANCIAL NEWS: ProNAi raises $59.5 million D round

    ProNAi Therapeutics Inc. (Kalamazoo, Mich.) raised $59.5 million in a series D round led by new investor Vivo Capital. New investors Frazier Healthcare Ventures; OrbiMed Advisors; Adams Street Partners; RA Capital …

    Published on 4/21/2014
  • FINANCIAL NEWS: Theravance raises $450 million for split

    Theravance Inc. (NASDAQ:THRX) raised $450 million through the sale of 9% notes due 2029. The proceeds will be used for Theravance's split into two publicly traded companies: one will focus on discovery and R&D of small …

    Published on 4/21/2014
  • FINANCIAL NEWS: Actelion reports first full quarter of Opsumit sales

    Actelion Ltd. (SIX:ATLN) reported CHF15 million ($16.9 million) in the first full quarter of sale of the pulmonary arterial hypertension (PAH) drug. The company launched the tissue-targeting endothelin receptor …

    Published on 4/17/2014
  • FINANCIAL NEWS: Ampio subsidiary Vyrix files for IPO

    The Vyrix Pharmaceutical Inc. subsidiary of Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) filed to raise up to $28.8 million in an IPO on NYSE MKT. Aegis Capital and Fordham are underwriters. Ampio carved off its sexual …

    Published on 4/17/2014
  • FINANCIAL NEWS: Fertility play Nora raises $18 million in series B

    Nora Therapeutics Inc. (Palo Alto, Calif.) raised $18 million in a series B round led by new investor Novo A/S. Existing investors Burrill; Prospect Venture Partners; Rho Ventures; and Vivo Capital also participated. …

    Published on 4/17/2014
  • FINANCIAL NEWS: Heart Metabolics secures $20 million in series A

    Heart Metabolics Ltd. (Dublin, Ireland) raised an undisclosed amount in the first tranche of a planned $20 million series A round from venBio; Seroba Kernal Life Sciences; Brandon Capital Partners; and AshHill. Heart …

    Published on 4/17/2014
  • FINANCIAL NEWS: AMD company Iconic closes $20 million round

    Iconic Therapeutics Inc. (Atlanta, Ga.) closed a $20 million series B round from new investors MPM Capital; Lundbeckfond Ventures; and H.I.G. BioVentures. Iconic is planning a Phase II trial of hI-con1 to treat wet age-…

    Published on 4/16/2014
  • FINANCIAL NEWS: ForSight Vision5 raises $15 million in series C

    ForSight Vision5 Inc. (Menlo Park, Calif.) raised $15 million in a series C round led by new investor H.I.G. BioVentures. Existing investors Morgenthaler Ventures; Versant Ventures; Technology Partners; and Delphi …

    Published on 4/16/2014
  • FINANCIAL NEWS: Foundation Medicine withdraws follow-on

    Pharmacogenetics company Foundation Medicine Inc. (NASDAQ:FMI) withdrew a proposed follow-on, citing market conditions. The company filed to raise $150 million in the offering last month, when its share price was $39.43…

    Published on 4/16/2014
  • FINANCIAL NEWS: Microlin Bio sets IPO range

    Microlin Bio Inc. (New York, N.Y.) amended its IPO on NASDAQ and now plans to sell 2.7 million shares at $10-$12. At the $11 midpoint, the company would raise $30 million and be valued at $75.1 million. Brean Capital …

    Published on 4/16/2014
  • FINANCIAL NEWS: Vital raises $54 million in IPO

    Liver disease company Vital Therapies Inc. (NASDAQ:VTL) raised $54 million through the sale of 4.5 million shares at $12 in an IPO underwritten by BofA Merrill Lynch; Credit Suisse; William Blair; and Canaccord. The …

    Published on 4/16/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993